You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

endocrine resistant

Showing 1 - 25 of 7,069
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer Trial in Singapore (Oral lenvatinib + Intravenous (IV)

Not yet recruiting
  • Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
  • Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole
  • Singapore, Singapore
    National Cancer Centre Singapore
Oct 13, 2022

Advanced Breast Cancer Trial in Shanghai (Pegylated Liposomal Doxorubicin)

Recruiting
  • Advanced Breast Cancer
  • Pegylated Liposomal Doxorubicin
  • Shanghai, China
    Fudan University Cancer Hospital
Apr 19, 2022

Breast Tumors Trial in Beijing, Nanjing, Changsha (Disitamab Vedotin, Toripalimab)

Not yet recruiting
  • Breast Neoplasms
  • Beijing, Cancer Hospital Chinese Academy Of Medical Sciences, China
  • +2 more
Oct 23, 2023

Metastatic Castration-resistant Prostate Cancer Trial (Disitamab Vedotin(RC48-ADC))

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Disitamab Vedotin（RC48-ADC）
  • (no location specified)
Jul 13, 2023

Breast Tumors, Endocrine Breast Diseases, Tumor Metastasis Trial in Baltimore (letrozole, lapatinib, everolimus)

Terminated
Has Results
  • Breast Neoplasms
  • +2 more
  • Baltimore, Maryland
    University of Maryland Marlene & Stewart Greenebaum Cancer Cente
Feb 9, 2022

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)

Not yet recruiting
  • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
  • (no location specified)
Sep 26, 2023

Breast Cancer Trial in Marseille (M1774, Fulvestrant injection)

Not yet recruiting
  • Breast Cancer
  • Marseille, France
    Institut Paoli Calmettes
Aug 9, 2023

Breast Tumor Female Trial in Hangzhou (anlotinib, fulvestrant)

Recruiting
  • Breast Neoplasm Female
  • anlotinib, fulvestrant
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 10, 2021

Metastatic Castration-resistant Prostate Cancer Trial in Nanjing (SHR7390)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Nanjing, Jiangsu, China
    The Affiliated Nanjing Drum Tower Hospital of Nanjing University
Feb 19, 2022

Metastatic Breast Cancer Trial in Jerusalem (Chemotherapy Drugs, Cancer)

Recruiting
  • Metastatic Breast Cancer
  • Chemotherapy Drugs, Cancer
  • Jerusalem, Israel
    Shaare Zedek Medical Center
Oct 22, 2020

Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +4 more
  • Birmingham, Alabama
  • +12 more
Nov 9, 2022

Ovarian Tumors, Fallopian Tube Tumors, Endocrine Gland Tumors Trial in Nanjing (Niraparib, Bevacizumab)

Unknown status
  • Ovarian Neoplasms
  • +23 more
  • Nanjing, Jiangsu, China
    JiangSu Cancer Hospital
Nov 8, 2020

Diabetes, Type II Trial in Asheville (Liraglutide, Insulin)

Completed
  • Diabetes Mellitus, Type II
  • Asheville, North Carolina
    Mountain Diabetes and Endocrine Center
Feb 23, 2021

Breast Cancer, Ovarian Cancer, Liposarcoma Trial (PF-07224826, Fulvestrant)

Not yet recruiting
  • Breast Cancer
  • +5 more
  • (no location specified)
Jun 7, 2023

Solid Tumors, Advanced Triple Negative Breast Cancer, Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer

Terminated
  • Solid Tumors
  • +4 more
  • Lafayette, Indiana
  • +3 more
Oct 23, 2020

Kidney Diseases, Diabetic Nephropathies, Glomerulosclerosis, Focal Segmental Trial in United States (GFB-887, Placebo)

Recruiting
  • Kidney Diseases
  • +10 more
  • Birmingham, Alabama
  • +75 more
Mar 29, 2022

Breast Cancer, Cancer of the Breast Trial in Saint Louis (VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based

Not yet recruiting
  • Breast Cancer
  • Cancer of the Breast
  • VENTANA MIB-1 Ki67 assay
  • +4 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Apr 18, 2023

Resistance in ER+ Breast Cancer Patients:Translational Project

Recruiting
  • Breast Cancer
    • Aviano, Pordenone, Italy
    • +1 more
    Nov 8, 2023

    Breast Cancer, Metastatic Cancer Trial in Shanghai (SHR7390, Famitinib, SHR3162)

    Recruiting
    • Breast Cancer
    • Metastatic Cancer
    • Shanghai, Shanghai, China
      Cancer Hospital Affiliated to Fudan University
    Jul 22, 2022

    Breast Cancer Female Trial in United Kingdom (Abemaciclib, Endocrine therapy)

    Recruiting
    • Breast Cancer Female
    • Abemaciclib
    • Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)
    • Truro, Cornwall, United Kingdom
    • +43 more
    Jan 23, 2023

    Hormone Receptor Positive Breast Carcinoma, Breast Tumors, Tumors, Breast Trial in Italy (Liquid biopsy and CT scan)

    Recruiting
    • Hormone Receptor Positive Breast Carcinoma
    • +6 more
    • Liquid biopsy and CT scan
    • Bergame, Bergamo, Italy
    • +6 more
    Apr 13, 2023

    Prostate Cancer, Prostate Carcinoma, Metastatic Castration-resistant Prostate Cancer Trial in Guangzhou (Olaparib)

    Recruiting
    • Prostate Cancer
    • +2 more
    • Guangzhou, China
      Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Feb 20, 2022

    Neoadjuvant Therapy, High Risk Prostate Cancer, Locally Advanced Prostate Cancer Trial in Nanjing (ADT, Abiraterone Acetate,

    Recruiting
    • Neoadjuvant Therapy
    • +3 more
    • Nanjing, Jiangsu, China
      Department of Urology, Drum Tower Hospital, Medical School of Na
    Aug 12, 2022

    Polycystic Ovary Syndrome Trial (TECADRIOL)

    Not yet recruiting
    • Polycystic Ovary Syndrome
    • TECADRIOL
    • (no location specified)
    Apr 22, 2022

    Metastatic Hormone-Sensitive Prostate Cancer Trial (Rezvilutamide, Rezvilutamide plus abiraterone, Continue previous treatment)

    Not yet recruiting
    • Metastatic Hormone-Sensitive Prostate Cancer
    • (no location specified)
    Nov 10, 2023